Cancer-Immune Equilibrium: Questions Unanswered

被引：35

作者：

Bhatia, Alka ^{[1
]}

Kumar, Yashwant ^{[1
]}

机构：

[1] PGIMER, Chandigarh, India

来源：

CANCER MICROENVIRONMENT | 2011年 / 4卷 / 02期

关键词：

Immunoediting; Elimination; Immune equilibrium; Escape; Mechanisms;

D O I：

10.1007/s12307-011-0065-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Cancer-immune (CI) equilibrium constitutes an important component of the cancer immunoediting theory. It is defined as a period during which our immune system and cancer live in harmony in the body. The immune system, though not able to completely eliminate the cancer, doesn't allow it to progress or metastasize further. Mechanisms of this phase are poorly understood because this phase is difficult to identify even by the most modern detection methods. Till now, the work done on the equilibrium phase of cancer, suggests promising improvements in cancer therapy if the disease could be withheld in this phase. However, there are many queries which remain to be addressed about this interesting yet unresolved phase of cancer immunity.

引用

收藏

页码：209 / 217

页数：9

相关论文

共 63 条

[1]

Models, mechanisms and clinical evidence for cancer dormancy [J].

Aguirre-Ghiso, Julio A. .

NATURE REVIEWS CANCER, 2007, 7 (11) :834-846

[2]

Cellular magnetic resonance imaging: current status and future prospects [J].

Arbab, Ali S. ;

Liu, Wei ;

Frank, Joseph A. .

EXPERT REVIEW OF MEDICAL DEVICES, 2006, 3 (04) :427-439

[3]

Tumor stem cell niches: A new functional framework for the action of anticancer drugs [J].

Baguley, Bruce C. .

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2006, 1 (01) :121-127

[4]

Does chemotherapy modify the immune surveillance of hematological malignancies? [J].

Barrett, A. J. ;

Savani, B. N. .

LEUKEMIA, 2009, 23 (01) :53-58

[5]

Bernardone I.S., 2008, INMUNOLOGIA, V27, P141, DOI [10.1016/S0213-9626(08)70062-3, DOI 10.1016/S0213-9626(08)70062-3]

[6]

A pooled analysis of bone marrow micrometastasis in breast cancer [J].

Braun, S ;

Vogl, FD ;

Naume, B ;

Janni, W ;

Osborne, MP ;

Coombes, RC ;

Schlimok, G ;

Diel, IJ ;

Gerber, B ;

Gebauer, G ;

Pierga, JY ;

Marth, C ;

Oruzio, D ;

Wiedswang, G ;

Solomayer, EF ;

Kundt, G ;

Strobl, B ;

Fehm, T ;

Wong, GYC ;

Bliss, J ;

Vincent-Salomon, A ;

Pantel, K .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) :793-802

[7]

High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma [J].

Carreras, Joaquim ;

Lopez-Guillermo, Armando ;

Fox, Bridget C. ;

Colomo, Lluis ;

Martinez, Antonio ;

Roncador, Giovanna ;

Montserrat, Emili ;

Campo, Elias ;

Banham, Alison H. .

BLOOD, 2006, 108 (09) :2957-2964

[8]

Platelet-associated PF-4 as a biomarker of early tumor growth [J].

Cervi, David ;

Yip, Tai-Tung ;

Bhattacharya, Nandita ;

Podust, Vladimir N. ;

Peterson, Jon ;

Abou-Slaybi, Abdo ;

Naumov, George N. ;

Bender, Elise ;

Almog, Nava ;

Italiano, Joseph E., Jr. ;

Folkman, Judah ;

Klement, Giannoula L. .

BLOOD, 2008, 111 (03) :1201-1207

[9]

Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.3.CO

[10]

2-0

← 1 2 3 4 5 6 7 →